It is never too late to stop smoking. Applying working estimates of smoking cessation on five-year overall survival gains after a cancer diagnosis

IF 2.4 3区医学 Q3 ONCOLOGY

Cancer Epidemiology Pub Date : 2025-03-18 DOI:10.1016/j.canep.2025.102775

Nouhad El-Haddad , Yang Li , Geoff P. Delaney , Heewon Kang , Shalini Vinod , Margo Barr , Takahiro Tabuchi , Michael Kidd , Freddy Sitas

{"title":"It is never too late to stop smoking. Applying working estimates of smoking cessation on five-year overall survival gains after a cancer diagnosis","authors":"Nouhad El-Haddad , Yang Li , Geoff P. Delaney , Heewon Kang , Shalini Vinod , Margo Barr , Takahiro Tabuchi , Michael Kidd , Freddy Sitas","doi":"10.1016/j.canep.2025.102775","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Detailed data on five-year overall survival (5Y-OS) in relation to smoking cessation after a cancer diagnosis are sparse. Implementation of smoking cessation in cancer treatment centres is also sub-optimal. The aim is to provide working, numeric estimates of 5Y-OS outcomes in relation to quitting smoking to help inform patients with cancer.</div></div><div><h3>Methods</h3><div>5Y-OS data and hazard ratios (HR) from a moderately sized cohort study from Japan were used to derive survival benefits on Australian cancer survival scenarios ranging from 10 % to 90 % 5Y survival, using standard epidemiological formulas comparing survival in those who recently quit around the time of their cancer diagnosis in comparison to those who continued to smoke.</div></div><div><h3>Results</h3><div>In a scenario of a cancer type with 90 % 5 y survival e.g. breast, prostate cancer, or melanoma, quitting smoking shows a gain in 5Y-OS of 10 %, and a gain in median survival of 2.1 years. In a scenario of 20 % 5 y survival (e.g. lung, liver, brain, or oesophageal cancer) recent quitting shows a 5Y-OS gain of 2 %, and a median survival gain of three months.</div></div><div><h3>Conclusion</h3><div>The greater the survival at presentation, the greater the gain by quitting smoking. Future research should aim to produce estimates based on real-world data.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"96 ","pages":"Article 102775"},"PeriodicalIF":2.4000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Epidemiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877782125000359","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Detailed data on five-year overall survival (5Y-OS) in relation to smoking cessation after a cancer diagnosis are sparse. Implementation of smoking cessation in cancer treatment centres is also sub-optimal. The aim is to provide working, numeric estimates of 5Y-OS outcomes in relation to quitting smoking to help inform patients with cancer.

Methods

5Y-OS data and hazard ratios (HR) from a moderately sized cohort study from Japan were used to derive survival benefits on Australian cancer survival scenarios ranging from 10 % to 90 % 5Y survival, using standard epidemiological formulas comparing survival in those who recently quit around the time of their cancer diagnosis in comparison to those who continued to smoke.

Results

In a scenario of a cancer type with 90 % 5 y survival e.g. breast, prostate cancer, or melanoma, quitting smoking shows a gain in 5Y-OS of 10 %, and a gain in median survival of 2.1 years. In a scenario of 20 % 5 y survival (e.g. lung, liver, brain, or oesophageal cancer) recent quitting shows a 5Y-OS gain of 2 %, and a median survival gain of three months.

Conclusion

The greater the survival at presentation, the greater the gain by quitting smoking. Future research should aim to produce estimates based on real-world data.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Epidemiology 医学-肿瘤学

CiteScore

4.50

自引率

3.80%

发文量

200

审稿时长

39 days

期刊介绍： Cancer Epidemiology is dedicated to increasing understanding about cancer causes, prevention and control. The scope of the journal embraces all aspects of cancer epidemiology including: • Descriptive epidemiology • Studies of risk factors for disease initiation, development and prognosis • Screening and early detection • Prevention and control • Methodological issues The journal publishes original research articles (full length and short reports), systematic reviews and meta-analyses, editorials, commentaries and letters to the editor commenting on previously published research.